Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer
Ölmez, Ömer Fatih
MetadataShow full item record
CitationBilici, A., Ölmez, Ö. F., Gürsoy, P., Çubukçu, E., Yıldız, Ö., Sakın, A. ... Hamdard, J. (2019). Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology içinde (S664-S665. ss.). https://doi.org/10.1016/j.jtho.2019.08.1407
The significance of the presence of a systemic inflammatory response (SIR) in predicting survival has been demonstrated in patients with cancer. Moreover, neutrophil-to-lymphocyte ratio (NLR), lymphocyteratio (NLR), lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) have been also investigated in patients with both early and advanced non-small-cell lung cancer (NSCLC). However, determination of SIR predicting outcomes of patients who are likely to response to crizotinib in ALK-positive NSCLC patients has not been clearly demonstrated.